In order to compare the clinical efficacy and safety of TMS-19-Q·GC tablet (TMS) with josamycin tablet (JM) in acute tonsillitis, the double blind trial was carried out with the daily dosage of 200 ...mg × 3 in TMS and 400 mg × 3 in JM. Number of cases evaluated for clinical efficacy were 154 cases (73 treated with TMS and 81 treated with JM). The effective rating of TMS and JM were 89.0% and 88.9% judged by doctors in charge, and 82.2% and 85.2% judged by committee respectively. Bacteriological effects were satisfactory to yield the eradica-tion rates of 93.8% in TMS and 94.7% in JM. Number of cases evaluated for safety were 199 cases (101 treated with TMS and 98 treated with JM). The incidence of side effect was 4.0% (4/101) in TMS and 5.1% (5/98) in JM and most of them were mild gastro-intestinal disorders. Number of cases evaluated for utility were 156 cases (74 treated with TMS and 82 treated with JM). The usefulness rates were 85.1% in TMS and 86.6% in JM. There was no significant difference between TMS and JM, in clinical effect, bacteriological effect, safety and utility. From these results, daily 600 mg dosage of TMS was as useful as daily 1,200 mg dosage of JM in the treatment for acute tonsillitis.
In order to evaluate the clinical usefulness of carbocisteine (S-CMC) in the treatment of chronic paranasal sinusitis, a double blind trial was carried out by comparing S-CMC with L-cysteine ...ethylester hydrochloride (L-cysteine) as a control drug. S-CMC group (S-Group) was administered orally two tablets of S-CMC and one placebo tablet in place of active L-cysteine (1,500mg of S-CMC/day), and L-cysteine group (L-Group) one tablet of L-cysteine and two placebo tablets in place of active S-CMC (300mg of L-cysteine/day) t, i, d, after meal for four weeks. Following results were obtained: 1) The ratio of excellent or good utility of S-Group was significantly higher than that of L-Group. 2) The ratio of marked or moderate improvement of S-Group was significantly higher than that of L-Group. 3) The improvement ratio for subjective and objective symptoms of S-Group was significantly higher than that in L-Group. 4) No significant difference was found in the judgement of X-ray findings between the two groups. 5) In the respective evaluation items classified as subjective symptoms (rhinorrhea, postnasal drip, nasal obstruction) and as objective symptoms (volume of rhinorrhea, mucus rhinorrhea, postnasal drip), S-Group showed significantly superior improvement ratio in those items to L-Group. 6) Side effects were observed in two cases (1.5%) in S-Group and one case (0.8%) in L-Group. The side effects were not serious and disappeared soon after the administration was discontinued. From the above results, it is concluded that S-CMC is highly effective in the treatment of chronic paranasal sinusitis.
PDF
